Epoprostenol vs Treprostinil (Tyvaso)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline
Epoprostenol · Flolan
Rights held by GlaxoSmithKline; US product discontinued
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Treprostinil (Tyvaso)
Marketed by United Therapeutics
NCT00147199 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 235 participants, with 115 receiving inhaled treprostinil and 120 receiving placebo. The prespecified clinical primary endpoint—change in peak 6-minute walk distance at Week 12—was met, with a between-group estimate of 20.0 meters (95% CI 8.0–32.8; p=0.00044).
Next expected readout: December 2027 · NCT07177703 (registry estimate)
Reported efficacy
Peak 6-minute Walk Distance (12 weeks): Peak 6-minute Walk Distance (12 weeks): Inhaled Treprostinil — Week 12: 366 meters (IQR 300 to 423); Change from Baseline: 21.6 meters (IQR -8 to 54) vs Placebo — Week 12: 360 meters (IQR 296 to 414.9); Change from Baseline: 3 meters (IQR -26 to 31.5) (met)
Result source: NCT00147199
Results for Pulmonary Arterial Hypertension
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Epoprostenol: 4 of 5 rows · Treprostinil (Tyvaso): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Epoprostenol | Treprostinil (Tyvaso) |
|---|---|---|
| 6MWD - Change absolute change · m No placebo or comparator arm | -3.55 m @ 4wka,b,c NCT01462565 · Phase 4 · registry result, not featured evidence | 20 m @ 12wka,b,c NCT01268553 · Phase 4 · registry result, not featured evidence 1 other source trial230 m @ 12wk NCT00705133 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 0%d NCT01462565 · Phase 4 · registry result, not featured evidence show 2 more results0% NCT01105117 · Phase 4 · registry result, not featured evidence 10% NCT01105091 · Phase 4 · registry result, not featured evidence | 11.3%e NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 3 more results0% NCT01268553 · Phase 4 · registry result, not featured evidence 11% NCT00741819 · Phase 4 · registry result, not featured evidence 0% NCT00705133 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —d NCT01462565 · Phase 4 · registry result, not featured evidence show 2 more results— NCT01105117 · Phase 4 · registry result, not featured evidence — NCT01105091 · Phase 4 · registry result, not featured evidence | —e NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 3 more results— NCT01268553 · Phase 4 · registry result, not featured evidence 4.1% NCT00741819 · Phase 4 · registry result, not featured evidence — NCT00705133 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 12.5%d NCT01462565 · Phase 4 · registry result, not featured evidence show 2 more results0% NCT01105117 · Phase 4 · registry result, not featured evidence 30% NCT01105091 · Phase 4 · registry result, not featured evidence | 7.8%e NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 3 more results0% NCT01268553 · Phase 4 · registry result, not featured evidence 13.7% NCT00741819 · Phase 4 · registry result, not featured evidence 0% NCT00705133 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | d diarrhoea 12.5% fatigue 12.5% headache 12.5% NCT01462565 · Phase 4 · registry result, not featured evidence show 2 more resultscatheter site erythema 100% flushing 0% NCT01105117 · Phase 4 · registry result, not featured evidence | e cough 53.9% (placebo 29.2%) headache 40.9% (placebo 22.5%) nausea 19.1% (placebo 10.8%) NCT00147199 · Phase 3 · monotherapy · Hypertension, Pulmonary Arterial Hypertension · phase 3 show 2 more resultsgeneral prostacyclin adverse reaction profile 100% NCT00705133 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation context differs: registered conditions differ.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 12 weeks versus 4 weeks.
- dPopulation comparability has not been reviewed for these studies.
- ePopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Epoprostenol
Treprostinil (Tyvaso)
show 1 more result
+ 2 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Epoprostenol's landscape · Treprostinil (Tyvaso)'s landscape